Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy

Table 2 Clinical characteristics of patients regarding PD-L1 expression

Characteristics	All, n	PD-L1 < 50%, n	(%)	PD-L1 ≥ 50, n	(%)	p
All patients	117	82	70.1	35	29.9
Age (years)						0.236
Median	61.0	60.5		64
Range	47–77	47–77		50–75
Gender						0.117
Female	38	23	28	15	42.9
Male	79	59	72	20	57.1
Histology						0.201
Squamous	71	48	58.5	23	65.7
Adeno	39	27	32.9	12	34.3
Other	7	7	8.5	0	0
Smoking status						0.702
Current	67	49	60.5	18	52.9
Former	44	29	35.8	15	44.2
Never	4	3	3.7	1	2.9
Stage						0.0230
IIIA	30	17	20.7	13	37.1
IIIB	75	59	72.0	16	45.7
IIIC	12	6	7.3	6	17.1
ECOG PS						0.625
0	58	41	50.0	17	48.6
1	57	39	47.6	18	51.4
2	2	2	2.4	0	0
RT dose (Gy)						0.639
Median		60		60
Range		54–66		54–66
ChT (number of cycles)						0.666
Median		3		3
Range		1–5		1–5
CRP after ChT/RT						0.447
≤ 2 × ULN	74	51	62.2	23	69.7
> 2 × ULN	41	31	37.8	10	30.3

ChT chemotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, n number, RT radiotherapy, CRP C-reactive protein, ULN upper limit of normal

ISSN: 1748-717X